Pacira Biosciences Inc. (PCRX)

36.54
NASDAQ : Health Technology
Prev Close 37.94
Day Low/High 36.40 / 38.15
52 Wk Low/High 35.07 / 55.00
Avg Volume 503.20K
Exchange NASDAQ
Shares Outstanding 41.63M
Market Cap 1.58B
P/E Ratio 199.68
Div & Yield N.A. (N.A)
Interesting PCRX Put And Call Options For January 2018

Interesting PCRX Put And Call Options For January 2018

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the January 2018 expiration.

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira Pharmaceuticals And TELA Bio Announce Equity Agreement

Pacira to invest up to $25 million in TELA Bio to enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair

First Week of PCRX May 2018 Options Trading

First Week of PCRX May 2018 Options Trading

Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the May 2018 expiration.

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

Pacira Pharmaceuticals Stock Sees Short Interest Expand By 13.7%

The most recent short interest data has been released for the 08/31/2017 settlement date, which shows a 637,865 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 5,288,719, an increase of 13.72% since 08/15/2017.

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

Pacira Pharmaceuticals, Aetna, And The American Association Of Oral And Maxillofacial Surgeons Join Together In A Program To Reduce Opioid Exposure For Patients Undergoing Wisdom Tooth Extraction

The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Pacira Pharmaceuticals Announces Multiple EXPAREL Data Presentations At The Upcoming New York School Of Regional Anesthesia Annual Fall Symposium

Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

Pacira Pharmaceuticals Stock Sees Short Interest Increase 53.8%

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,627,603 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 4,650,854, an increase of 53.84% since 07/31/2017.

New Research Shows Vast Majority Of Oral Surgery Patients Would Choose Non-opioid Medication To Treat Postsurgical Pain If Given The Option

Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction    

TheStreet Quant Rating: C (Hold)